Theravance Biopharma Inc (TBPH) — Cash Flow-to-Debt Ratio
Theravance Biopharma Inc (TBPH) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of $-6.06 Million could theoretically repay 0% of its total liabilities ($188.85 Million) in one year. See Theravance Biopharma Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Theravance Biopharma Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Theravance Biopharma Inc across 15 annual periods. Also explore TBPH net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Theravance Biopharma Inc (2011–2025)
Year-by-year debt coverage analysis for Theravance Biopharma Inc. For market capitalisation and broader financial context, see TBPH stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.26x | $238.54 Million | $188.85 Million | ▲ +2055.9% |
| 2024 | -0.06x | $-11.54 Million | $178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | $-27.00 Million | $169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | $-186.99 Million | $165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | $-207.86 Million | $713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | $-250.40 Million | $772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | $-238.20 Million | $632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | $-112.87 Million | $611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | $-201.05 Million | $326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | $-98.99 Million | $289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | $-168.86 Million | $57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | $-175.16 Million | $47.98 Million | ▼ -27.4% |
| 2013 | -2.87x | $-120.96 Million | $42.21 Million | ▲ +45.5% |
| 2012 | -5.25x | $-119.11 Million | $22.67 Million | ▼ -873.2% |
| 2011 | -0.54x | $-83.43 Million | $154.54 Million | — |